Key Takeaways
- Merck (MRK) signed voluntary licensing deals with seven generic manufacturers to expand access to its experimental HIV pill, alimatravir, across 129 countries.
- AstraZeneca (AZN) received a positive EU CHMP recommendation for Trixeo Aerosphere as a maintenance treatment for asthma, potentially reaching 43 million patients in Europe.
- The Russian Central Bank unexpectedly cut its key interest rate by 25 basis points to 14.00%, defying market expectations of a hold at 14.25%.
- The Israel Defense Forces (IDF) launched wide-ranging operations in the West Bank following a deadly shooting attack near the Havat Gilad settlement that left one Israeli and four Palestinians dead.
Merck Accelerates Global HIV Prevention Strategy
Merck (MRK) has initiated a comprehensive supply plan for alimatravir (MK-8527), an investigational once-monthly oral medication for HIV-1 prevention. The pharmaceutical giant entered into non-exclusive voluntary licensing agreements with seven manufacturers, including Aurobindo (AUROPHARMA), Cipla (CIPLA), Emcure, and Viatris (VTRS) in India, alongside Aspen, Quality Chemical Industries, and UCL Kenya in Africa.
These agreements cover 129 low- and middle-income countries, regions that represent the majority of new HIV diagnoses globally. This proactive licensing strategy aims to ensure generic production can scale up even as Phase 3 clinical trials continue. Merck is also in active discussions with Fiocruz to facilitate availability in Latin America and Brazil, where HIV incidence remains a significant public health challenge.
AstraZeneca’s Trixeo Moves Toward EU Asthma Approval
AstraZeneca (AZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended Trixeo Aerosphere for approval in the European Union. The recommendation is for the maintenance treatment of asthma in patients aged 12 and older whose symptoms are not adequately controlled by dual-therapy inhalers.
The positive opinion is supported by data from the KALOS and LOGOS Phase 3 trials, which demonstrated that the triple-combination therapy significantly improved lung function compared to standard dual therapies. If approved, Trixeo—already marketed as Breztri in the US and China for COPD—will provide a new single-inhaler option for millions of Europeans suffering from uncontrolled asthma.
Russian Central Bank Issues Surprise Rate Cut
In a move that caught markets off guard, the Bank of Russia reduced its benchmark interest rate to 14.00% from 14.25%. Most analysts had expected the central bank to maintain the rate due to persistent inflationary pressures and a tightening labor market.
The bank revised its 2026 GDP growth forecast downward to a range of 0.0% to 1.0% while raising its inflation outlook to 6.0%–7.0%. Policymakers cited a moderate pace of economic activity and a sharp rise in fuel prices as primary drivers for the current monetary stance. The bank indicated that future decisions would depend heavily on the sustainability of the inflation slowdown.
IDF Bolsters West Bank Presence After Fatal Attack
The IDF has announced plans for comprehensive operations in the West Bank following a "severe terror attack" near the Havat Gilad settlement. The incident involved a shooting that resulted in the death of one Israeli civilian and four Palestinians.
IDF Chief of Staff Lt. Gen. Eyal Zamir has ordered a broad reinforcement of forces to strengthen defense in the area and capture individuals involved in the attack. The military has imposed a temporary cordon around Nablus and the village of Tell as operations continue. This escalation follows a period of flared violence in the northern West Bank, prompting calls from local leaders for a more robust security response.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.